|
Volumn 109, Issue 6, 2002, Pages
|
Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens.
a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MEASLES MUMPS RUBELLA VACCINE;
VIRUS ANTIBODY;
ACUTE LYMPHOCYTIC LEUKEMIA;
ADOLESCENT;
ADULT;
ANTIBODY PRODUCTION;
ARTICLE;
BLOOD;
BONE MARROW CELL;
CHILD;
FEMALE;
FLOW CYTOMETRY;
FLUORESCENT ANTIBODY TECHNIQUE;
HUMAN;
IMMUNE DEFICIENCY;
IMMUNIZATION;
IMMUNOLOGY;
INFANT;
MALE;
MEASLES;
MEASLES VIRUS;
PLASMA CELL;
PRESCHOOL CHILD;
RUBELLA;
RUBELLA VIRUS;
ADOLESCENT;
ADULT;
ANTIBODIES, VIRAL;
ANTIBODY FORMATION;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BONE MARROW CELLS;
CHILD;
CHILD, PRESCHOOL;
FEMALE;
FLOW CYTOMETRY;
FLUORESCENT ANTIBODY TECHNIQUE;
HUMANS;
IMMUNIZATION SCHEDULE;
IMMUNIZATION, SECONDARY;
IMMUNOCOMPROMISED HOST;
INFANT;
LEUKEMIA, LYMPHOCYTIC, ACUTE;
MALE;
MEASLES;
MEASLES VIRUS;
MEASLES-MUMPS-RUBELLA VACCINE;
PLASMA CELLS;
RUBELLA;
RUBELLA VIRUS;
|
EID: 0036595208
PISSN: None
EISSN: 10984275
Source Type: Journal
DOI: 10.1542/peds.109.6.e91 Document Type: Article |
Times cited : (113)
|
References (0)
|